ADVANCE infectious diseases pharmacy and LEAD antimicrobial stewardship in order
to OPTIMIZE the care of patients

  • Home
  • Remdesivir for 5 or 10 Days in Patients with Severe COVID-19

Remdesivir for 5 or 10 Days in Patients with Severe COVID-19

02 Jun 2020 9:53 AM | Daniel Hawley (Administrator)

New England Journal of Medicine:
https://www.nejm.org/doi/full/10.1056/NEJMoa2015301

Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe COVID-19. N Engl J Med. May 27, 2020 [Epub Ahead of Print]. DOI:10.1056/NEJMoa2015301

View Journal Club Review


SIDP appreciates all feedback on our journal club reviews. To leave a comment or ask a question, please fill out this form. Comments for this review will close on June 6, 2020.


Society of Infectious Diseases Pharmacists •  110 E. Schiller St., Suite 230, Elmhurst, IL 60126
(331) 248-7888sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software